Skip to content

EV / EBITDA at other companies

Abbott logo
AbbottABT
18.9×-4.1×
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
TFX
TeleflexTFX
26.8×+7.6×
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8×+4.2×
Stryker logo
StrykerSYK
22.1×-11.8×
Boston Scientific logo
Boston ScientificBSX
28.3×-8.5×

Other financials

Income statement

See full
Revenue$381.9M+7.5%
Gross profit$184.8M+7.4%
Operating income$44.2M+7.6%
Net income$41.0M+36.0%
EPS (diluted)$0.68+38.8%

Balance sheet

See full
Cash & equivalents$488.1M+23.4%
Total debt$821.6M+0.5%
Total equity$1.6B+13.9%
Total assets$2.7B+10.2%

Cash flow

See full
Operating cash flow$40.7M+0.3%
CapEx$16.0M-24.0%
Free cash flow$24.7M+26.5%

Valuation

See full
Market cap$4.01B-34.1%
Enterprise value$4.34B-33.3%
P/E28.8×-21.0×
P/S2.6×-1.8×

Profitability

See full
Gross margin48.7%+0.9pp
Operating margin12.2%+0.6pp
Net margin9%+0.2pp
FCF margin14.3%+1.3pp

Returns & leverage

See full
Return on equity9.1%0.0pp
Debt / equity0.5×-0.1×
Current ratio5.1×+0.2×

Where this comes from

Calculated from Merit Medical Systems’s reported figures.

Based on the most recent quarter.

The official record: Merit Medical Systems’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merit Medical Systems's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merit Medical Systems's EV / EBITDA?
Merit Medical Systems (MMSI) reported EV / EBITDA of 14.2× in Q1 2026.
How has Merit Medical Systems's EV / EBITDA changed year-over-year?
Merit Medical Systems's EV / EBITDA decreased by 42.5% year-over-year, from 24.7× to 14.2×.
What is the long-term trend for Merit Medical Systems's EV / EBITDA?
Over 5 years (2020 to 2025), Merit Medical Systems's EV / EBITDA has grown at a -13.7% compound annual growth rate (CAGR), from 38× to 18.2×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.